Results 21 to 30 of about 1,821 (152)

Effects of catechins, resveratrol, silymarin components and some of their conjugates on xanthine oxidase‐catalyzed xanthine and 6‐mercaptopurine oxidation

Journal of the Science of Food and Agriculture, Volume 105, Issue 5, Page 2765-2776, 30 March 2025.
Abstract BACKGROUND Over the past two decades, the global incidence of gout has markedly increased, affecting people worldwide. Considering the side effects of xanthine oxidase (XO) inhibitor drugs (e.g. allopurinol and febuxostat) used in the treatment of hyperuricemia and gout, the potential application of phytochemicals has been widely studied.
Tímea Bencsik, Orsolya Balázs, Róbert G Vida, Balázs Z Zsidó, Csaba Hetényi, Kateřina Valentová, Miklós Poór   +6 more
wiley   +1 more source

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Daidzein Ameliorate Hyperuricemia by Upregulating ABCG2 Expression via Activation of PPARγ and PI3K/AKT Pathways

Food Frontiers, Volume 7, Issue 2, March 2026.
Hyperuricaemia is a chronic metabolic disorder arising from impaired purine metabolism, exhibiting marked gender disparities in its prevalence. Daidzein, possessing oestrogen‐like effects, promotes uric acid excretion and improves hepatic and renal function, thereby presenting potential utility as an adjunctive therapeutic agent for hyperuricaemia ...
Zicheng Zhu, Jujie Pan, Ruixia Bao, Beibei Chen, Siyi Li, Ziyu Che, Qian Chen, Yuzheng Wu, Dan Wang, Tao Wang   +9 more
wiley   +1 more source

Anti‐Arthritic Potential of Pyrazoline Derivative Against Complete Freund's Adjuvant Induced Arthritis in Rats

Journal of Cellular and Molecular Medicine, Volume 30, Issue 4, February 2026.
ABSTRACT This research explored the potential of a synthesised pyrazoline derivative 5‐ethoxy 5‐hydroxy 3‐methyls 4, 5‐dihydro 1Hpyrazol 1 yl (pyridine 4 yl) methanone [5‐E‐5‐H‐PD], against arthritis using a Complete Freund's Adjuvant (CFA)‐induced arthritis in a rat model.
Jian Li, Irfan Anjum, Halima Qadir, Faiza Naseer, Mehreen Arif, Muhammad Riaz, Rabia Gul, Madiha Kanwal, Bei Zhuang   +8 more
wiley   +1 more source

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad

Drug Design, Development and Therapy, 2017
Graeme Jones,1 Elena Panova,1 Richard Day2 1Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; 2University of New South Wales, Medicine, St Vincent’s Hospital, Sydney, NSW, Australia Abstract: The aim of this ...
Jones G, Panova E, Day R
doaj  

Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China

Arthritis &Rheumatology, Volume 77, Issue 12, Page 1757-1766, December 2025.
Objective Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicenter, randomized, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad ...
Jia Sun, Yu Wang, Yongjing Cheng, Dongmei Guo, Jiankang Hu, Dongzhou Liu, Zhengnan Gao, Changgui Li, Yibing Lu, Xiaodan Kong, Yu Liu, Zhenyu Jiang, Bin Yi, Hongfeng Zhang, Baijie Xu, Shihao Yu, Rieko Kokan, Kohei Ishikawa, Mikiko Kawakatsu, Zhuoli Zhang   +19 more
wiley   +1 more source

Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New‐User Active Comparator Cohort Study

Nephrology, Volume 30, Issue 11, November 2025.
This retrospective cohort study assessed the cardiovascular outcomes in people with chronic kidney disease who were newly prescribed allopurinol or febuxostat. ABSTRACT Aim Hyperuricaemia, a common comorbidity among people with chronic kidney disease, is widely treated with uric acid‐lowering agents such as allopurinol and febuxostat.
Reiko Inoue, Satoko Yamaguchi, Akira Okada, Toshimasa Yamauchi, Takashi Kadowaki, Masaomi Nangaku   +5 more
wiley   +1 more source

CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation

Health Science Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background and Aims Biomarkers are essential tools in the diagnosis and management of various diseases. Rheumatoid arthritis (RA) is a systemic inflammatory disorder that frequently results in damage to joints and organs. Here, we examined potential biomarkers and therapeutic agents for RA patients.
Chuanhui Yao, Hui Xu, Xun Gong, Xieli Ma, Yuchen Yang, Dan Dou, Qiuwei Peng, Juan Jiao, Xiaopo Tang, Quan Jiang, Congmin Xia   +10 more
wiley   +1 more source

Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions

Journal of Evaluation in Clinical Practice, Volume 31, Issue 7, October 2025.
ABSTRACT Background Pharmacological therapy in older persons is inherently complex due to the interplay of age‐related physiological changes, multimorbidity, and polypharmacy. These factors increase the vulnerability of elderly patients to drug interactions and adverse drug reactions.
N. N. Ngcobo
wiley   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

Arthritis Care &Research, Volume 77, Issue 9, Page 1149-1156, September 2025.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun, Lingling Cui, Robert Terkeltaub, Ying Chen, Xinde Li, Xiaoyu Cheng, Tian Liu, Nicola Dalbeth, Changgui Li   +8 more
wiley   +1 more source